Sivik Global Healthcare LLC Increases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sivik Global Healthcare LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,000 shares of the medical research company's stock after buying an additional 1,500 shares during the period. Thermo Fisher Scientific accounts for 2.7% of Sivik Global Healthcare LLC's portfolio, making the stock its 16th biggest position. Sivik Global Healthcare LLC's holdings in Thermo Fisher Scientific were worth $6,369,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Linden Thomas Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 8.8% in the third quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company's stock worth $783,000 after buying an additional 125 shares during the period. Harbor Capital Advisors Inc. raised its holdings in Thermo Fisher Scientific by 17.7% in the third quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the medical research company's stock worth $628,000 after purchasing an additional 187 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 99,703 shares of the medical research company's stock valued at $50,467,000 after buying an additional 835 shares in the last quarter. FAS Wealth Partners Inc. increased its stake in shares of Thermo Fisher Scientific by 7.8% in the 3rd quarter. FAS Wealth Partners Inc. now owns 748 shares of the medical research company's stock worth $378,000 after acquiring an additional 54 shares in the last quarter. Finally, RMR Wealth Builders bought a new stake in Thermo Fisher Scientific during the third quarter worth about $722,000. Institutional investors own 89.23% of the company's stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,277 shares of company stock valued at $29,649,264. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on TMO. Citigroup started coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They set a "neutral" rating and a $620.00 price objective for the company. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research note on Thursday, April 25th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating on the stock in a research report on Thursday, April 25th. HSBC boosted their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a "buy" rating in a research report on Thursday, April 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $607.35.

Thermo Fisher Scientific Price Performance

TMO traded down $8.15 during trading on Tuesday, reaching $568.74. 1,514,866 shares of the company traded hands, compared to its average volume of 1,554,109. The company has a market cap of $217.09 billion, a P/E ratio of 36.48, a PEG ratio of 2.41 and a beta of 0.80. The firm has a fifty day simple moving average of $574.58 and a 200 day simple moving average of $531.67. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts' consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.